ArticleStroke (Hoboken, N.J.)2023
Trends in Thrombolysis and Thrombectomy Use in Patients With Ischemic Stroke and Cancer.
Article in Stroke (Hoboken, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mechanical Thrombectomy in Patients with Malignancy: Comparable Procedural Success but Less Favorable Long-Term Outcomes.Brain sciences · 2026Article
- Endovascular treatment in ischemic stroke with active cancer: retrospective analysis of university stroke center data.Neurological research and practice · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To determine how intravenous thrombolysis (IV-tPA) and mechanical thrombectomy (MT) use has changed in patients with acute ischemic stroke (AIS) with cancer (AIS-C) compared with patients with AIS and noncancer (AIS-NC) in the United States since publication of pivotal MT trials. Methods: All primary AIS-NC and AIS-C admissions (weighted N=5 748 357) were identified from the 2007 to 2019 Nationwide Inpatient Sample. Joinpoint and multivariable-adjusted models with interaction terms were used to compare the rate of change in IV-tPA and MT use between AIS-C and AIS-NC. Results: From 2007 to 2019, 4.4% of AIS admissions had active cancer. Overall IV-tPA use in AIS-C (6.4%) was lower than that of AIS-NC (8.5%) ( Conclusions: Use of IV-tPA and MT has increased in AIS-C over the past decade. Contrary to prior studies, the current frequency and pace of increase in MT use is greater in metastatic AIS-C compared with AIS-NC. Future studies are needed to determine whether AIS-C are more predisposed to large-vessel occlusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.